ACADIA Pharmaceuticals Inc.
NASDAQ:ACADBiotechnology
-$0.13 today
- Market cap
- $3.08B
- Beta
- 0.83
- P/E (TTM)
- 9.7
- EPS (TTM)
- $2.20
Volume 1.89M
Average 1.66M
ACAD Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
ACADIA Pharmaceuticals Inc.NASDAQ: ACAD
Other Non-Cash Items · Q2 FY2026 · quarter ended Jun 2026
Other non-cash items turns positive
Q2 FY2026 other non-cash items was $15.69M, compared with -$1.54M a year earlier. Trailing-twelve-month other non-cash items was $26.7M.
Context
- Other non-cash items amounted to 4.4% of revenue in FY2025, down 11.9 pp from a year earlier.
- Other non-cash items increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other non-cash items holds near $15.69M or moves back toward the trailing-twelve-month quarterly average of $6.68M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 46.71M USD
- Year-over-year change
- +130.0%
- 4-year CAGR
- +399.6%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.71M | +130.0% |
| FY2024 | 2024-12-31 | (155.82M) | -1185.8% |
| FY2023 | 2023-12-31 | (12.12M) | -93.0% |
| FY2022 | 2022-12-31 | (6.28M) | -8470.7% |
| FY2021 | 2021-12-31 | 75K | — |
Other Non-Cash Items vs competitors
How ACAD compares with its peers on the latest reported figures
- ACAD's LTM Jun 2026 other non-cash items of $26.7M is the 2nd largest of the 11 companies compared; the peer median is $2.87M.
- Its year-over-year change of +117.1% is the 7th highest of 9, against a peer median of +175.4%.
- Other non-cash items amounts to 2.3% of revenue for ACAD, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $44.04M | +20871.7% | +213.8% | — | |
| LTM Jun 2026 | $26.7M | +117.1% | — | 2.3% | |
| LTM Sep 2026 | $25.15M | +862.4% | — | — | |
| LTM Jun 2026 | $6.22M | -88.5% | +25.2% | 0.8% | |
| LTM Mar 2026 | $4.01M | +59.1% | +61.6% | — | |
| LTM Mar 2026 | $3.74M | +252.3% | — | 1.7% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $2.01M | — | -33.1% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.66M | +167.4% | -60.9% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.03M | +118.7% | -50.7% | 5.2% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $562K | +183.4% | -52.2% | — |
| LTM Dec 2025 | $0 | — | — | — | |
| Peer median (excluding ACAD) | $2.87M | +175.4% | -33.1% | 1.7% | |
Competitors are the stored peer set for ACAD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (167.87M) | (215.98M) | (61.29M) | 226.45M | 391M |
| Depreciation & Amortization | 3.34M | 2.03M | 5.55M | 15.88M | 11.76M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (249.88M) |
| Stock-Based Compensation | 63.62M | 68.2M | 66.42M | 67.05M | 0 |
| Change in Working Capital | (24.82M) | 37.99M | 18.13M | 4.16M | (89.76M) |
| Accounts Receivables | (16.12M) | 2.26M | (39.27M) | (2.35M) | (43.54M) |
| Inventory | (4.21M) | 2.42M | (28.81M) | (49.55M) | (18.2M) |
| Accounts Payables | (1.62M) | 5.87M | 4.8M | (1.35M) | (5.29M) |
| Other Working Capital | (2.88M) | 27.44M | 81.41M | 57.4M | (22.73M) |
| Other Non-Cash Items | 75K | (6.28M) | (12.12M) | (155.82M) | 46.71M |
| Operating Cash Flow | (125.66M) | (114.04M) | 16.7M | 157.72M | 109.84M |
| Capital Expenditures | (1.12M) | 0 | (40.05M) | (523K) | (4.69M) |
| Acquisitions (Net) | 69.98M | 0 | (32.05M) | 0 | 0 |
| Purchases of Investments | (492.8M) | (363.17M) | (369.99M) | (505.1M) | (692.57M) |
| Sales of Investments | 422.82M | 436.42M | 442.03M | 328.57M | 493.53M |
| Other Investing Activities | (69.98M) | 0 | 32.05M | 146.52M | 0 |
| Investing Cash Flow | (71.1M) | 73.24M | 32M | (30.54M) | (302.56M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 18.16M | 8.2M | 25.13M | 6.85M | 49.88M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 18.16M | 8.2M | 25.13M | 6.85M | 49.88M |
| Effect of Forex Changes | 7K | 6K | (18K) | (94K) | 951K |
| Net Change in Cash | (178.59M) | (32.59M) | 73.81M | 133.93M | (141.89M) |
| Free Cash Flow | (126.78M) | (114.04M) | (23.35M) | 157.2M | 105.15M |
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
Intrinsic Alpha fair value
Locked
Current Price
$17.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.